Which Patients have Greatest Need for Elvitegravir/Cobicistat/ Emtricitabine/TenofovirDF-Based Therapy?
Recent Patents on Anti-Infective Drug Discovery,
Antonio Di Biagio, Roberta Prinapori, Lucia Taramasso, Giulia Gustinetti, Laura Sticchi, Bianca Bruzzone and Claudio ViscoliAffiliation:
InfectiousDiseases Unit, IRCCS A.O.U. San Martino- IST, Genoa, Italy, Largo R. Benzi, 10, 16132 Genoa, Italy.
AbstractElvitegravir/cobicistat/emtricitabine/tenofovirDF (EVG/COBI/FTC/TDF) is the new single-tablet, fixed-dose formulation containing an integrase strand transfer inhibitor recently approved as antiretroviral treatment. In this paper we analysed its use and advantages in naïve and experienced HIV-infected patients and we focused on special populations in which EVG/COBI/FTC/TDF could be a suitable option. Furthermore the manuscript reports the recent patent of EVG which may have an influence on the management of HIV-infected patients in the next future.
Cobicistat, elvitegravir, emtricitabine, resistance, side effects, tenofovirDF.
Download Free Order Reprints Order Eprints Rights and Permissions